New treatment for adults with classic congenital adrenal hyperplasia
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new medicine (NBIP-01435) to see if it helps adults with classic congenital adrenal hyperplasia better manage their condition. The goal is to improve hormone levels and potentially allow for lower steroid doses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.
- You've been on a stable dose of your steroid (glucocorticoid) medication for at least 30 days.
- If you take fludrocortisone, your dose must be stable for 30 days and your renin level (a blood test) should be within normal limits.
- You must have elevated androstenedione (a hormone) in your blood at screening.
- You weigh at least 50 kg (110 lbs) if you're male, or at least 45 kg (100 lbs) if you're female.
- You're not pregnant and agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication for children with classic congenital adrenal hyperplasia (CAH). It aims to see if the drug helps better control hormone levels and reduce the need for high doses of current steroid medicines.
This study tests a new drug, atumelnant, for adults with classic congenital adrenal hyperplasia (CAH) caused by 21-OHD. It aims to see if it can help control hormone levels while allowing lower doses of current steroid medications.
This early study tests Lu AG13909 in people with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. It aims to see how the drug affects hormone levels and whether it is safe for different CAH hormone patterns.
This trial studies whether a once-daily hydrocortisone tablet works as well as standard steroid treatment for adults with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. It aims to improve how safely and conveniently hormone replacement is taken each day.
This study tests a new medicine called crinecerfont in children under 4 years old with classic congenital adrenal hyperplasia (CAH), a condition where the body doesn't make certain hormones properly. Researchers want to learn if the medicine is safe and how it works in the body.
This trial is creating a registry to track adult males with congenital adrenal hyperplasia (CAH) from 21-hydroxylase deficiency. It helps doctors learn more about the condition and how it changes over time.
Hear when a new Congenital Adrenal Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.